Standard
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β. / Simpson-Yap, Steve; Pirmani, Ashkan; De Brouwer, Edward; Peeters, Liesbet M.; Geys, Lotte; Parciak, Tina; Helme, Anne; Hillert, Jan; Moreau, Yves; Edan, Gilles; Spelman, Tim; Sharmin, Sifat; McBurney, Robert; Schmidt, Hollie; Bergmann, Arnfin; Braune, Stefan; Stahmann, Alexander; Middleton, Rodden; Salter, Amber; Bebo, Bruce; van der Walt, Anneke; Butzkueven, Helmut; Ozakbas, Serkan; Karabudak, Rana; Boz, Cavit; Alroughani, Raed; Rojas, Juan I.; van der Mei, Ingrid; Sciascia do Olival, Guilherme; Magyari, Melinda; Alonso, Ricardo; Nicholas, Richard; Chertcoff, Anibal; Zabalza, Ana; Arrambide, Georgina; Nag, Nupur; Descamps, Annabel; Costers, Lars; Dobson, Ruth; Miller, Aleisha; Rodrigues, Paulo; Prčkovska, Vesna; Comi, Giancarlo; Kalincik, Tomas.
In:
Multiple Sclerosis and Related Disorders, Vol. 66, 104072, 2022.
Research output: Contribution to journal › Letter › Research › peer-review
Harvard
Simpson-Yap, S, Pirmani, A, De Brouwer, E, Peeters, LM, Geys, L, Parciak, T, Helme, A, Hillert, J, Moreau, Y, Edan, G, Spelman, T, Sharmin, S, McBurney, R, Schmidt, H, Bergmann, A, Braune, S, Stahmann, A, Middleton, R, Salter, A, Bebo, B, van der Walt, A, Butzkueven, H, Ozakbas, S, Karabudak, R, Boz, C, Alroughani, R, Rojas, JI, van der Mei, I, Sciascia do Olival, G, Magyari, M, Alonso, R, Nicholas, R, Chertcoff, A, Zabalza, A, Arrambide, G, Nag, N, Descamps, A, Costers, L, Dobson, R, Miller, A, Rodrigues, P, Prčkovska, V, Comi, G & Kalincik, T 2022, '
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β',
Multiple Sclerosis and Related Disorders, vol. 66, 104072.
https://doi.org/10.1016/j.msard.2022.104072APA
Simpson-Yap, S., Pirmani, A., De Brouwer, E., Peeters, L. M., Geys, L., Parciak, T., Helme, A., Hillert, J., Moreau, Y., Edan, G., Spelman, T., Sharmin, S., McBurney, R., Schmidt, H., Bergmann, A., Braune, S., Stahmann, A., Middleton, R., Salter, A., ... Kalincik, T. (2022).
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.
Multiple Sclerosis and Related Disorders,
66, [104072].
https://doi.org/10.1016/j.msard.2022.104072Vancouver
Simpson-Yap S, Pirmani A, De Brouwer E, Peeters LM, Geys L, Parciak T et al.
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.
Multiple Sclerosis and Related Disorders. 2022;66. 104072.
https://doi.org/10.1016/j.msard.2022.104072Author
Simpson-Yap, Steve ; Pirmani, Ashkan ; De Brouwer, Edward ; Peeters, Liesbet M. ; Geys, Lotte ; Parciak, Tina ; Helme, Anne ; Hillert, Jan ; Moreau, Yves ; Edan, Gilles ; Spelman, Tim ; Sharmin, Sifat ; McBurney, Robert ; Schmidt, Hollie ; Bergmann, Arnfin ; Braune, Stefan ; Stahmann, Alexander ; Middleton, Rodden ; Salter, Amber ; Bebo, Bruce ; van der Walt, Anneke ; Butzkueven, Helmut ; Ozakbas, Serkan ; Karabudak, Rana ; Boz, Cavit ; Alroughani, Raed ; Rojas, Juan I. ; van der Mei, Ingrid ; Sciascia do Olival, Guilherme ; Magyari, Melinda ; Alonso, Ricardo ; Nicholas, Richard ; Chertcoff, Anibal ; Zabalza, Ana ; Arrambide, Georgina ; Nag, Nupur ; Descamps, Annabel ; Costers, Lars ; Dobson, Ruth ; Miller, Aleisha ; Rodrigues, Paulo ; Prčkovska, Vesna ; Comi, Giancarlo ; Kalincik, Tomas. / Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β. In: Multiple Sclerosis and Related Disorders. 2022 ; Vol. 66.
Bibtex
@article{fd779115072f478db4915f0fd53c9660,
title = "Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β",
abstract = "Background: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. Results: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs. Conclusions: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.",
author = "Steve Simpson-Yap and Ashkan Pirmani and {De Brouwer}, Edward and Peeters, {Liesbet M.} and Lotte Geys and Tina Parciak and Anne Helme and Jan Hillert and Yves Moreau and Gilles Edan and Tim Spelman and Sifat Sharmin and Robert McBurney and Hollie Schmidt and Arnfin Bergmann and Stefan Braune and Alexander Stahmann and Rodden Middleton and Amber Salter and Bruce Bebo and {van der Walt}, Anneke and Helmut Butzkueven and Serkan Ozakbas and Rana Karabudak and Cavit Boz and Raed Alroughani and Rojas, {Juan I.} and {van der Mei}, Ingrid and {Sciascia do Olival}, Guilherme and Melinda Magyari and Ricardo Alonso and Richard Nicholas and Anibal Chertcoff and Ana Zabalza and Georgina Arrambide and Nupur Nag and Annabel Descamps and Lars Costers and Ruth Dobson and Aleisha Miller and Paulo Rodrigues and Vesna Pr{\v c}kovska and Giancarlo Comi and Tomas Kalincik",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",
year = "2022",
doi = "10.1016/j.msard.2022.104072",
language = "English",
volume = "66",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
}
RIS
TY - JOUR
T1 - Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
AU - Simpson-Yap, Steve
AU - Pirmani, Ashkan
AU - De Brouwer, Edward
AU - Peeters, Liesbet M.
AU - Geys, Lotte
AU - Parciak, Tina
AU - Helme, Anne
AU - Hillert, Jan
AU - Moreau, Yves
AU - Edan, Gilles
AU - Spelman, Tim
AU - Sharmin, Sifat
AU - McBurney, Robert
AU - Schmidt, Hollie
AU - Bergmann, Arnfin
AU - Braune, Stefan
AU - Stahmann, Alexander
AU - Middleton, Rodden
AU - Salter, Amber
AU - Bebo, Bruce
AU - van der Walt, Anneke
AU - Butzkueven, Helmut
AU - Ozakbas, Serkan
AU - Karabudak, Rana
AU - Boz, Cavit
AU - Alroughani, Raed
AU - Rojas, Juan I.
AU - van der Mei, Ingrid
AU - Sciascia do Olival, Guilherme
AU - Magyari, Melinda
AU - Alonso, Ricardo
AU - Nicholas, Richard
AU - Chertcoff, Anibal
AU - Zabalza, Ana
AU - Arrambide, Georgina
AU - Nag, Nupur
AU - Descamps, Annabel
AU - Costers, Lars
AU - Dobson, Ruth
AU - Miller, Aleisha
AU - Rodrigues, Paulo
AU - Prčkovska, Vesna
AU - Comi, Giancarlo
AU - Kalincik, Tomas
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022
Y1 - 2022
N2 - Background: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. Results: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs. Conclusions: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.
AB - Background: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. Results: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs. Conclusions: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.
U2 - 10.1016/j.msard.2022.104072
DO - 10.1016/j.msard.2022.104072
M3 - Letter
C2 - 35917745
AN - SCOPUS:85135173300
VL - 66
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
M1 - 104072
ER -
